Publication Type : Journal Article
Publisher : Pharmaceuticals
Source : Pharmaceuticals, 2021, 14(11),1148, DOI: 10.3390/ph14111148
Url : https://pubmed.ncbi.nlm.nih.gov/34832930/
Keywords : MAO-B; ROS; chalcone; cytotoxicity; molecular dynamics; reversibility; selectivity.
Campus : Kochi
School : School of Pharmacy
Department : Pharmaceutical Chemistry & Analysis
Year : 2021
Abstract : To develop new potent and highly selective MAO-B inhibitors from chalcone-thioethers, eleven chalcones-thioethers were synthesized and their monoamine oxidase (MAO) inhibition, kinetics, reversibility, and cytotoxicity of lead compounds were analyzed. Molecular dynamics were carried out to investigate the interactions. Compound TM8 showed potent inhibitory activity against MAO-B, with an IC50 value of 0.010 µM, followed by TM1, TM2, TM7, and TM10 (IC50 = 0.017, 0.021, 0.023, and 0.026 µM, respectively). Interestingly, TM8 had an extremely high selectivity index (SI; 4860) for MAO-B. Reversibility and kinetic experiments showed that TM8 and TM1 were reversible and competitive inhibitors of MAO-B with Ki values of 0.0031 ± 0.0013 and 0.011± 0.001 µM, respectively. Both TM1 and TM8 were non-toxic to Vero cells with IC50 values of 241.8 and 116.3 µg/mL (i.e., 947.7 and 402.4 µM), respectively, and at these IC50 values, both significantly reduced reactive oxygen species (ROS) levels. TM1 and TM8 showed high blood-brain barrier permeabilities in the parallel artificial membrane permeability assay. Molecular dynamics studies were conducted to investigate interactions between TM1 and TM8 and the active site of MAO-B. Conclusively, TM8 and TM1 are potent and highly selective MAO-B inhibitors with little toxicity and good ROS scavenging abilities and it is suggested that both are attractive prospective candidates for the treatment of neurological disorders.
Cite this Research Publication : Mathew, B., Oh, J.M., Khames, A., Mathew, G.E., Kim, H. Replacement of chalcone-ethers with chalcone-thioethers as potent and highly selective monoamine oxidase-b inhibitors and their protein-ligand interactions, Pharmaceuticals, 2021, 14(11),1148, DOI: 10.3390/ph14111148